Fig. 3
Thioreoxin deletion limits hematopoietic stem cells reconstitution ability in a murine model. A competitive transplantation: Bone marrow cells (1 × 105) harvested at day 10 from TAM treated- TXN1fl/fl (control) and ROSA-CreER-TXN1fl/fl mice were mixed with competitor bone marrow cells (1 × 105) harvested from CD45.1 C57bl/6 J and injected into lethally irradiated (9.5 Gy total body irradiation) CD45.1 C57bl/6 J. Peripheral blood CD45.2 cells derived from TXN1fl/fl (control) and ROSA-CreER-TXN1fl/fl mice were measured at indicated time-points (weeks 4, 8 and 12). B Schematic figure of limiting competitive bone marrow transplant: SLAM + KSL cells were sorted by flow cytometry from the bone marrow cells harvested at day 10 from TAM treated- TXN1fl/fl (control) and ROSA-CreER-TXN1fl/fl mice. Two cell doses (50 SLAM + KSL cells or 200 SLAM + KSL cells) were mixed with competitor bone marrow cells (1 × 105) harvested from CD45.1 C57bl/6J and injected into lethally irradiated (9.5 Gy total body irradiation) CD45.1 C57bl/6J. C–H Peripheral blood CD45.2 cells derived from TXN1fl/fl (control) and ROSA-Cre-TXN1fl/fl mice were measured at indicated time-points in the first transplant recipient mice (month 1, 6, 9 and 10). The 1st transplant recipient mice were sacrificed at 10 months after transplant. Bone marrow cells were harvested and injected into second, lethally irradiated (9.5 Gy total body irradiation) CD45.1 C57bl/6J mice (5 × 106 cells per mouse). Peripheral blood CD45.2 cells derived from TXN1fl/fl (control) and ROSA-CreER-TXN1fl/fl mice were measured at indicated time-points in the secondary transplant recipient mice (month 2, 3, 4). The second transplant recipient mice were sacrificed at 4 months and bone marrow cells were harvested and injected iv into third lethally irradiated (9.5 Gy total body irradiation) CD45.1 C57bl/6J mice (5 × 106 cells per mouse). Peripheral blood CD45.2 cells in the tertiary transplant recipient mice were followed. **p < 0.01; ***p < 0.001